Carmen Cristina Diaconu

Dr. Carmen Cristina Diaconu

Stefan S. Nicolau Institute of Virology, Romanian Academy, Bucharest, Bucureşti, Romania

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
SCSven Cichon
Sven Cichon
TMThomas W. Mühleisen
Thomas W. Mühleisen
FDFranziska A. Degenhardt
Franziska A. Degenhardt
MMManuel Mattheisen
Manuel Mattheisen
XMXavier Miró
Xavier Miró
MNMarkus M. Nöthen
Markus M. Nöthen

1 January 2015 in World Journal of Stem Cells
Verified
Journal Article
Open access
DDDenisa L Dragu
Denisa L Dragu
MEMihaela Economescu
Mihaela Economescu
CDCarmen Cristina Diaconu
Carmen Cristina Diaconu
Coralia BleotuCoralia Bleotu
Coralia Bleotu
LNLaura G Necula
Laura G Necula
Therapies targeting cancer stem cells: Current trends and future challenges

Verified
Journal Article
Open access
PDF file
LNLaura Necula
Laura Necula
LMLilia Matei
Lilia Matei
LDLaura Denisa Dragu
Laura Denisa Dragu
IPIoana Madalina Pitica
Ioana Madalina Pitica
ANAna Neagu
Ana Neagu
MEMihaela Economescu
Mihaela Economescu
Despite advances in cancer detection and therapy, it has been estimated that the incidence of cancers will increase, while the mortality rate will continue to remain high, a fact explained by the large number of patients diagnosed in advanced stages when therapy is often useless. Therefore, it is necessary to invest knowledge and resources in the development of new non-invasive biomarkers for the early detection of cancer and new therapeutic targets for better health management. In this review, we provided an overview on the collagen family as promising biomarkers and on how they may be exploited as therapeutic targets in cancer. The collagen family tridimensional structure, organization, and functions are very complex, being in a tight relationship with the extracellular matrix, tumor, and immune microenvironment. Moreover, accumulating evidence underlines the role of collagens in promoting tumor growth and creating a permissive tumor microenvironment for metastatic dissemination. Knowledge of the molecular basis of these interactions may help in cancer diagnosis and prognosis, in overcoming chemoresistance, and in providing new targets for cancer therapies.

6 September 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
VAVeronica Mãdãlina Aspriţoiu
Veronica Mãdãlina Aspriţoiu
ISIleana Stoica
Ileana Stoica
Coralia BleotuCoralia Bleotu
Coralia Bleotu
CDCarmen Cristina Diaconu
Carmen Cristina Diaconu
Angiogenesis is a multi-stage process of new blood vessel development from pre-existing vessels toward an angiogenic stimulus. The process is essential for tissue maintenance and homeostasis during embryonic development and adult life as well as tumor growth. Under normal conditions, angiogenesis is involved in physiological processes, such as wound healing, cyclic regeneration of the endometrium, placental development and repairing certain cardiac damage, in pathological conditions, it is frequently associated with cancer development and metastasis. The control mechanisms of angiogenesis in carcinogenesis are tightly regulated at the genetic and epigenetic level. While genetic alterations are the critical part of gene silencing in cancer cells, epigenetic dysregulation can lead to repression of tumor suppressor genes or oncogene activation, becoming an important event in early development and the late stages of tumor development, as well. The global alteration of the epigenetic spectrum, which includes DNA methylation, histone modification, chromatin remodeling, microRNAs, and other chromatin components, is considered one of the hallmarks of cancer, and the efforts are concentrated on the discovery of molecular epigenetic markers that identify cancerous precursor lesions or early stage cancer. This review aims to highlight recent findings on the genetic and epigenetic changes that can occur in physiological and pathological angiogenesis and analyze current knowledge on how deregulation of epigenetic modifiers contributes to tumorigenesis and tumor maintenance. Also, we will evaluate the clinical relevance of epigenetic markers of angiogenesis and the potential use of “epi-drugs” in modulating the responsiveness of cancer cells to anticancer therapy through chemotherapy, radiotherapy, immunotherapy and hormone therapy as anti-angiogenic strategies in cancer.

17 May 2012 in Blood
Verified
Journal Article
Open access
PDF file
CPChristian Pecquet
Christian Pecquet
CDCarmen Cristina Diaconu
Carmen Cristina Diaconu
JSJudith Staerk
Judith Staerk
MGMichael Girardot
Michael Girardot
CMCaroline Marty
Caroline Marty
SCStefan N. Constantinescu
Stefan N. Constantinescu
The constitutively active JAK2 V617F mutant is the major determinant of human myeloproliferative neoplasms (MPNs). We show that coexpression of murine JAK2 V617F and the murine thrombopoietin (Tpo) receptor (TpoR, c-MPL) in hematopoietic cell lines or heterozygous knock-in of JAK2 V617F in mice leads to down-modulation of TpoR levels. Enhanced TpoR ubiquitinylation, proteasomal degradation, reduced recycling, and maturation are induced by the constitutive JAK2 V617F activity. These effects can be prevented in cell lines by JAK2 and proteasome inhibitors. Restoration of TpoR levels by inhibitors could be detected in platelets from JAK2 inhibitor-treated myelofibrosis patients that express the JAK2 V617F mutant, and in platelets from JAK2 V617F knock-in mice that were treated in vivo with JAK2 or proteasome inhibitors. In addition, we show that Tpo can induce both proliferative and antiproliferative effects via TpoR at low and high JAK2 activation levels, respectively, or on expression of JAK2 V617F. The antiproliferative signaling and receptor down-modulation by JAK2 V617F were dependent on signaling via TpoR cytosolic tyrosine 626. We propose that selection against TpoR antiproliferative signaling occurs by TpoR down-modulation and that restoration of down-modulated TpoR levels could become a biomarker for the treatment of MPNs.

19 November 2013 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
MCMeng Ling Choong
Meng Ling Choong
CPChristian Pecquet
Christian Pecquet
VPVishal Pendharkar
Vishal Pendharkar
CDCarmen Cristina Diaconu
Carmen Cristina Diaconu
JYJacklyn Wei Yan Yong
Jacklyn Wei Yan Yong
MLMay Ann Lee
May Ann Lee
Current JAK2 inhibitors used for myeloproliferative neoplasms (MPN) treatment are not specific enough to selectively suppress aberrant JAK2 signalling and preserve physiological JAK2 signalling. We tested whether combining a JAK2 inhibitor with a series of serine threonine kinase inhibitors, targeting nine signalling pathways and already used in clinical trials, synergized in inhibiting growth of haematopoietic cells expressing mutant and wild‐type forms of JAK2 (V617F) or thrombopoietin receptor (W515L). Out of 15 kinase inhibitors, the ZSTK474 phosphatydylinositol‐3′‐kinase (PI3K) inhibitor molecule showed strong synergic inhibition by Chou and Talalay analysis with JAK2 and JAK2/JAK1 inhibitors. Other pan‐class I, but not gamma or delta specific PI3K inhibitors, also synergized with JAK2 inhibitors. Synergy was not observed in Bcr‐Abl transformed cells. The best JAK2/JAK1 and PI3K inhibitor combination pair (ruxolitinib and GDC0941) reduces spleen weight in nude mice inoculated with Ba/F3 cells expressing TpoR and JAK2 V617F. It also exerted strong inhibitory effects on erythropoietin‐independent erythroid colonies from MPN patients and JAK2 V617F knock‐in mice, where at certain doses, a preferential inhibition of JAK2 V617F mutated progenitors was detected. Our data support the use of a combination of JAK2 and pan‐class I PI3K inhibitors in the treatment of MPNs.